Stelara(ustekinumab)
Imuldosa, Otulfi, Pyzchiva, Selarsdi, Stelara, Wezlana (ustekinumab) is an antibody pharmaceutical. Ustekinumab was first approved as Stelara on 2009-01-15. It is used to treat crohn disease and psoriatic arthritis in the USA. It has been approved in Europe to treat crohn disease, psoriasis, psoriatic arthritis, and ulcerative colitis. The pharmaceutical is active against interleukin-12 subunit beta.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Imuldosa, Otulfi, Pyzchiva, Selarsdi, Stelara, Steqeyma, Wezlana, Yesintek (discontinued: Stelara)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Ustekinumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Stelara | ustekinumab | Johnson & Johnson | N-125261 RX | 2009-09-25 | 3 products |
| Stelara | ustekinumab | Johnson & Johnson | N-761044 RX | 2016-09-23 | 1 products |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| imuldosa | Biologic Licensing Application | 2026-06-17 |
| otulfi | Biologic Licensing Application | 2026-02-16 |
| pyzchiva | Biologic Licensing Application | 2026-07-09 |
| selarsdi | Biologic Licensing Application | 2026-06-24 |
| starjemza | Biologic Licensing Application | 2025-10-24 |
| stelara | Biologic Licensing Application | 2026-07-21 |
| steqeyma | Biologic Licensing Application | 2026-04-07 |
| ustekinumab | Biologic Licensing Application | 2026-07-23 |
| ustekinumab-aauz | Biologic Licensing Application | 2026-02-26 |
| ustekinumab-aekn | Biologic Licensing Application | 2026-07-30 |
Show 3 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
265 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Crohn disease | D003424 | EFO_0000384 | K50 | 4 | 7 | 16 | 12 | 50 | 87 |
| Psoriasis | D011565 | EFO_0000676 | L40 | 8 | 4 | 37 | 11 | 22 | 82 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | 1 | 2 | 5 | 5 | 26 | 39 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | 1 | 1 | 5 | 3 | 21 | 31 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 2 | — | 1 | 1 | 4 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | 1 | — | 1 |
| Netherton syndrome | D056770 | — | — | — | — | — | 1 | — | 1 |
| Lamellar ichthyosis | D017490 | — | Q80 | — | — | — | 1 | — | 1 |
| Ichthyosis vulgaris | D016112 | — | Q80.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | 4 | 8 | — | 14 | 26 |
| Colitis | D003092 | EFO_0003872 | K52.9 | 1 | — | 5 | — | 5 | 11 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | 1 | — | 9 | 10 |
| Ulcer | D014456 | MPATH_579 | — | 1 | 1 | 2 | — | 4 | 8 |
| Skin diseases | D012871 | — | L00-L99 | — | — | 4 | — | 2 | 6 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | 2 | 2 | — | 2 | 6 |
| Intestinal diseases | D007410 | — | K63.9 | 1 | 1 | 1 | — | 2 | 4 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | 2 | 2 | — | — | 4 |
| Spondylarthritis | D025241 | — | — | — | 1 | 1 | — | 2 | 4 |
| Spondylitis | D013166 | — | M46.9 | — | — | 1 | — | 3 | 4 |
Show 13 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 2 | — | — | 4 | 6 |
| Inflammation | D007249 | MP_0001845 | — | — | 2 | — | — | 2 | 4 |
| Giant cell arteritis | D013700 | EFO_1001209 | M31.6 | 1 | 3 | — | — | — | 3 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | 1 | 3 | — | — | — | 3 |
| Behcet syndrome | D001528 | EFO_0003780 | M35.2 | — | 2 | — | — | 1 | 3 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | 1 | — | — | 1 | 2 |
| Polymyalgia rheumatica | D011111 | EFO_0008518 | M35.3 | 1 | 2 | — | — | — | 2 |
| Eczema | D004485 | — | L30.9 | — | 2 | — | — | — | 2 |
| Graft vs host disease | D006086 | — | D89.81 | — | 1 | — | — | — | 1 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | 1 | — | — | — | 1 |
Show 18 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 8 | — | — | — | — | 8 |
| Ichthyosis | D007057 | — | E50.8 | 1 | — | — | — | — | 1 |
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 2 | 2 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | — | 1 | 1 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
| Hepatitis b | D006509 | — | — | — | — | — | — | 1 | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | — | — | 1 | 1 |
| Necrosis | D009336 | — | — | — | — | — | — | 1 | 1 |
| Pathologic constriction | D003251 | — | — | — | — | — | — | 1 | 1 |
| Intestinal obstruction | D007415 | — | K56.60 | — | — | — | — | 1 | 1 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | — | — | 1 | 1 |
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ustekinumab |
| INN | ustekinumab |
| Description | Ustekinumab, sold under the brand name Stelara, is a human monoclonal antibody used to treat psoriasis. It is also approved to treat Crohn's disease in the United States, Israel and Australia, and ulcerative colitis in the U.S., and in the European Union (EU) among people who have not responded to more traditional treatments. |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >3HMW:H|USTEKINUMAB FAB HEAVY CHAIN
EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAY
LQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSSSSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW
NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTH
>3HMW:L|USTEKINUMAB FAB LIGHT CHAIN
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQP
EDFATYYCQQYNIYPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 3HMW, 3HMX |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201835 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB05679 |
| UNII ID | FU77B4U5Z0 (ChemIDplus, GSRS) |
Target
Agency Approved
IL12B
IL12B
Organism
Homo sapiens
Gene name
IL12B
Gene synonyms
NKSF2
NCBI Gene ID
Protein name
interleukin-12 subunit beta
Protein synonyms
CLMF p40, Cytotoxic lymphocyte maturation factor 40 kDa subunit, IL-12 subunit p40, IL12, subunit p40, interleukin 12, p40, interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40), interleukin-12 beta chain, natural killer cell stimulatory factor, 40 kD subunit, NK cell stimulatory factor chain 2, NKSF2
Uniprot ID
Mouse ortholog
Il12b (16160)
interleukin-12 subunit beta (Q9QUM1)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Stelara – Johnson & Johnson
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
92,307 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use